Ken Griffin Monte Rosa Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 60,600 shares of GLUE stock, worth $376,932. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,600

Previous 69,700 13.06%

Holding current value

$376,932

Previous $369,000 13.82%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$4.8 - $10.36 $1.83 Million - $3.94 Million	-380,583 Reduced 32.84%	778,386 $5.4 Million
Q3 2024 Nov 14, 2024	BUY	$3.59 - $6.97 $585,263 - $1.14 Million	163,026 Added 16.37%	1,158,969 $6.14 Million
Q2 2024 Aug 14, 2024	BUY	$3.38 - $7.86 $53,079 - $123,433	15,704 Added 1.6%	995,943 $3.72 Million
Q1 2024 May 15, 2024	SELL	$4.26 - $8.46 $15,105 - $29,999	-3,546 Reduced 0.36%	980,239 $6.91 Million
Q4 2023 Feb 14, 2024	BUY	$2.5 - $5.93 $382,937 - $908,327	153,175 Added 18.44%	983,785 $5.56 Million
Q3 2023 Nov 14, 2023	BUY	$4.78 - $7.22 $281,283 - $424,868	58,846 Added 7.62%	830,610 $3.98 Million
Q2 2023 Aug 14, 2023	BUY	$4.53 - $8.4 $7,986 - $14,809	1,763 Added 0.23%	771,764 $5.29 Million
Q1 2023 May 15, 2023	SELL	$5.95 - $8.21 $1.21 Million - $1.68 Million	-204,194 Reduced 20.96%	770,001 $6 Million
Q4 2022 Feb 14, 2023	BUY	$6.71 - $9.72 $142,513 - $206,443	21,239 Added 2.23%	974,195 $7.41 Million
Q3 2022 Nov 14, 2022	BUY	$7.17 - $12.16 $5.97 Million - $10.1 Million	833,124 Added 695.24%	952,956 $7.79 Million

Others Institutions Holding GLUE

# of Institutions

107

Shares Held

53.8M

Call Options Held

276K

Put Options Held

15.9K

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $291M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account